CBIO
Crescent Biopharma, Inc.
14.50$
+3.9%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -15.4% | -12.5% | +203.3% | +67.1% | -21.8% | -15.0% | -33.9% | -45.1% | -12.5% | -21.4% | +574.7% | |
| – | -15.8% | -14.2% | +214.0% | +66.9% | -23.4% | -14.9% | -34.3% | -44.1% | -13.7% | -20.5% | +580.0% | |
| – | -15.2% | -14.4% | +209.5% | +69.4% | -24.6% | -13.4% | -34.1% | -47.0% | -12.7% | -16.8% | +513.2% | |
| – | -15.2% | -14.4% | +209.5% | +69.4% | -24.6% | -13.4% | -34.1% | -47.0% | -12.7% | -16.8% | +513.2% | |
| – | +73.2% | +594.5% | -62.1% | +305.2% | -55.0% | -98.8% | -37.3% | +10,591.6% | +22.1% | -22.3% | +13,079.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +23.7% | -11.3% | +25.3% | +5.6% | +46.9% | +6.1% | -12.8% | -30.3% | -22.3% | +640.3% | -27.0% | |
| – | +19.9% | -18.2% | +29.1% | +7.2% | +25.0% | +13.5% | -4.9% | -24.9% | -23.0% | +40.7% | +275.2% | |
| – | – | – | – | – | – | +11.7% | +11.4% | -8.3% | -19.3% | -91.0% | +550.8% | |
| – | -35.4% | +177.4% | +69.1% | +0.6% | -46.1% | +45.6% | +0.8% | -54.0% | -10.5% | -87.7% | +9,243.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -20.3% | -12.8% | +239.1% | +71.6% | -25.0% | -16.8% | -36.4% | -47.4% | -10.5% | -140.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.0% | +11.8% | +38.3% | +39.6% | +5.4% | +5.7% | +12.5% | +2.1% | +20.6% | +21.2% | +1,256.7% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.